These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 26822949)
1. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients. Lhota F; Zemankova P; Kleiblova P; Soukupova J; Vocka M; Stranecky V; Janatova M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z Clin Genet; 2016 Oct; 90(4):324-33. PubMed ID: 26822949 [TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926 [TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859 [TBL] [Abstract][Full Text] [Related]
4. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836 [TBL] [Abstract][Full Text] [Related]
5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
6. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer. Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441 [TBL] [Abstract][Full Text] [Related]
8. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063 [TBL] [Abstract][Full Text] [Related]
9. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698 [TBL] [Abstract][Full Text] [Related]
10. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176 [TBL] [Abstract][Full Text] [Related]
11. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310 [TBL] [Abstract][Full Text] [Related]
12. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249 [TBL] [Abstract][Full Text] [Related]
13. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
14. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182 [TBL] [Abstract][Full Text] [Related]
15. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497 [TBL] [Abstract][Full Text] [Related]
17. Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey. Cecener G; Guney Eskiler G; Egeli U; Tunca B; Alemdar A; Gokgoz S; Tasdelen I Mol Biol Rep; 2016 Nov; 43(11):1273-1284. PubMed ID: 27573125 [TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. Pern F; Bogdanova N; Schürmann P; Lin M; Ay A; Länger F; Hillemanns P; Christiansen H; Park-Simon TW; Dörk T PLoS One; 2012; 7(10):e47993. PubMed ID: 23110154 [TBL] [Abstract][Full Text] [Related]
19. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930 [TBL] [Abstract][Full Text] [Related]
20. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]. Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]